Company Overview

TG Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases, with a primary emphasis on multiple sclerosis (MS). The company operates within the biotechnology and pharmaceutical industries and is publicly traded on NASDAQ under the ticker TGTX. Its core business is the discovery, clinical development, regulatory approval, and commercialization of novel, targeted biologic therapies.

The company’s primary revenue driver is BRIUMVI® (ublituximab-xiiy), a monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis. TG Therapeutics differentiates itself through its focus on optimized antibody engineering and streamlined commercialization as a single-product company. Founded in 1997, TG Therapeutics initially pursued oncology indications but strategically pivoted toward autoimmune diseases, culminating in the FDA approval of BRIUMVI in 2022, which marked a major inflection point in its corporate evolution.

Business Operations

TG Therapeutics operates as a single-reportable-segment biotechnology company, generating revenue primarily from U.S. sales of BRIUMVI®, which targets CD20-positive B cells and competes in the anti-CD20 MS therapy class. Commercial activities include sales, marketing, medical affairs, and post-marketing clinical studies, while research and development efforts are focused on lifecycle management and potential label expansion.

The company conducts its commercial operations primarily in the United States, while aspects of clinical development, regulatory strategy, and supply chain management involve international vendors and partners. TG Therapeutics relies on third-party manufacturers for drug substance and drug product manufacturing and maintains control over intellectual property, regulatory approvals, and commercialization strategy. The company previously marketed Umbralisib, an oncology product, but discontinued and withdrew it from the market following regulatory and safety developments.

Strategic Position & Investments

TG Therapeutics’ strategic direction is centered on establishing BRIUMVI® as a competitive long-term therapy in the MS market by emphasizing dosing efficiency, clinical efficacy, and commercial access. Growth initiatives include expanding market penetration in the U.S., pursuing ex-U.S. regulatory approvals through partnerships, and conducting additional clinical and real-world evidence studies to support broader adoption.

The company has made targeted investments in manufacturing scale-up, commercial infrastructure, and post-approval clinical programs rather than broad portfolio acquisitions. TG Therapeutics has also entered into regional licensing and commercialization agreements outside the U.S., enabling international expansion without building a full global commercial footprint. Its strategic focus remains tightly aligned with autoimmune disease treatment rather than diversification into unrelated therapeutic areas.

Geographic Footprint

TG Therapeutics is headquartered in the United States, with corporate offices in New York. Its primary commercial presence and revenue generation are concentrated in North America, specifically the U.S. MS treatment market. Clinical trial activity and regulatory engagement have extended to Europe and other international regions through partnerships and contract research organizations.

International influence is primarily investment- and partnership-based rather than operational, with non-U.S. commercialization efforts structured through regional collaborators. The company does not currently maintain large-scale international manufacturing or sales operations, reflecting its strategy to remain lean while selectively expanding global reach.

Leadership & Governance

TG Therapeutics was founded by Michael S. Weiss, who continues to play a central role in shaping the company’s long-term strategy. The leadership team emphasizes disciplined capital allocation, focused portfolio management, and execution efficiency following the transition to a commercial-stage company. Governance practices align with U.S. public company standards, with oversight by an independent board of directors.

Key executives include:

• Michael S. Weiss – Chairman of the Board, President, and Chief Executive Officer
• Sean McKenna – Chief Financial Officer
• G. Michael O’Neill – Chief Operating Officer
• Anthony M. Mancini – Chief Legal Officer and Corporate Secretary

The leadership philosophy centers on maintaining strategic focus on core assets, prioritizing regulatory compliance and patient safety, and driving shareholder value through disciplined growth execution.